Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Jilin Maifeng Rabies Vaccine (Vero Cell) is an inactivated viral vaccine produced by Jilin Maifeng Biotech Pharmaceutical Co., Ltd. for the prevention of rabies in humans. The vaccine is manufactured using Vero cell culture technology and is administered via intramuscular injection, typically following the Essen (1-1-1-1-1) or Zagreb (2-1-1) immunization schedules. It is designed to induce active immunity by stimulating the production of neutralizing antibodies against the rabies virus. In the context of clinical trials in China, such as those sponsored by the Jiangsu Province Centers for Disease Control and Prevention, it is commonly employed as a standard-of-care comparator to evaluate the safety and immunogenicity of novel rabies vaccine candidates.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Jilin Maifeng Rabies Vaccine (Vero Cell).